Rigel Pharmaceuticals Investor Relations Material
Latest events
Q1 2025
Rigel Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Rigel Pharmaceuticals Inc
Access all reports
Rigel Pharmaceuticals Inc. is a biotechnology company focused on discovering, developing, and commercializing small-molecule drugs for immune and hematologic disorders, as well as rare diseases. The company’s research and development efforts target critical pathways in the immune system to address conditions with significant unmet medical needs. Rigel also partners with other pharmaceutical companies to advance its therapeutic candidates. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for Rigel Pharmaceuticals Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Rigel Pharmaceuticals Inc
Q1 2025
Rigel Pharmaceuticals Inc
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
RIGL
Country
🇺🇸 United States